"Oncolytic Viruses" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumor-selective, replication competent VIRUSES that have antineoplastic effects. This is achieved by producing cytotoxicity-enhancing proteins and/or eliciting an antitumor immune response. They are genetically engineered so that they can replicate in CANCER cells but not in normal cells, and are used in ONCOLYTIC VIROTHERAPY.
Descriptor ID |
D050504
|
MeSH Number(s) |
B04.700
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oncolytic Viruses".
Below are MeSH descriptors whose meaning is more specific than "Oncolytic Viruses".
This graph shows the total number of publications written about "Oncolytic Viruses" by people in this website by year, and whether "Oncolytic Viruses" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 1 | 0 | 1 |
2008 | 1 | 0 | 1 |
2009 | 1 | 1 | 2 |
2010 | 1 | 0 | 1 |
2013 | 1 | 1 | 2 |
2014 | 3 | 0 | 3 |
2016 | 2 | 0 | 2 |
2017 | 1 | 0 | 1 |
2018 | 2 | 0 | 2 |
2020 | 2 | 1 | 3 |
2021 | 3 | 0 | 3 |
2023 | 2 | 0 | 2 |
2024 | 1 | 1 | 2 |
2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncolytic Viruses" by people in Profiles.
-
IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity. Nat Commun. 2025 Apr 24; 16(1):3874.
-
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial. Nat Med. 2025 Jan; 31(1):144-151.
-
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. J Immunother Cancer. 2024 Dec 09; 12(12).
-
Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas. Viruses. 2024 Nov 14; 16(11).
-
The emerging field of viroimmunotherapy for pediatric brain tumors. Neuro Oncol. 2024 Nov 04; 26(11):1981-1993.
-
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models. Neuro Oncol. 2024 08 05; 26(8):1509-1525.
-
Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believing. J Immunother Cancer. 2024 Jun 17; 12(6).
-
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nat Med. 2024 Aug; 30(8):2216-2223.
-
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 Apr; 25(4):488-500.
-
Oncolytic adenoviruses and immunopeptidomics: a?convenient marriage. Mol Oncol. 2024 Apr; 18(4):781-784.